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Key Messages
 First study to investigate the impact of mass drug administration (MDA) for trachoma 
elimination on M. genitalium prevalence and azithromycin resistance. 
 In this Solomon Islands antenatal care population, MDA with self-reported coverage of 
approximately 50%, did not appear to impact M. genitalium prevalence or azithromycin 
resistance
 However, in those who reported receiving azithromycin as part of MDA, we found reduced 
odds of M. genitalium infection
 Overall there was evidence suggestive of M. genitalium strain replacement following MDA.
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Abstract
Background: Mass Drug Administration (MDA) of 20mg/kg (maximum 1g in adults) azithromycin for 
ocular Chlamydia trachomatis (CT) infection is a key component of the WHO trachoma elimination 
strategy. However, this dose may be suboptimal in M. genitalium infection and may encourage 
emergence of antimicrobial resistance (AMR) to azithromycin. 
Objectives: To determine the effect of MDA for trachoma elimination on M. genitalium prevalence, 
strain type and azithromycin resistance
Methods: A secondary analysis of CT-negative vulvovaginal swabs from three outpatient antenatal 
clinics (Honiara, Solomon Islands) from patients recruited either pre-MDA, or 10 months post-MDA 
in two cross-sectional surveys was carried out. Swabs were tested for M. genitalium infection using 
Fast Track Diagnostics Urethritis Plus nucleic acid amplification assay. M. genitalium positive samples 
were subsequently tested for azithromycin resistance by sequencing domain V of the 23S rRNA DNA 
region of M. genitalium and underwent phylogenetic analysis by dual locus sequence typing.
Results: M. genitalium prevalence was 11.9% (28/236) in women pre-MDA and 10.9% (28/256) 10 
months post-MDA (p=0.7467). Self-reported receipt of azithromycin as part of MDA was 49.2% in 
women recruited post-MDA and 17.9% (5/28) in those who tested M. genitalium positive. Of 
samples sequenced (21/28 pre-MDA, 22/28 post-MDA), all showed a macrolide susceptible 
genotype. Strain typing showed that sequence types diverged into two lineages, with a suggestion of 
strain replacement post-MDA.
Conclusion: A single round of azithromycin MDA in an island population with high baseline M. 
genitalium prevalence did not appear to impact on either prevalence or azithromycin resistance, in 
contrast to reported decreased genital CT prevalence in the same population. This may be due to 
limitations such as sample size, including CT-negative samples only, and low MDA coverage. Further 
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investigation of the impact of multiple rounds of MDA on M. genitalium azithromycin AMR in 
antibiotic experienced and naïve populations is warranted.
Background 
Mycoplasma genitalium is a sexually transmitted infection (STI) of increasing global importance, 
causing serious maternal and child health sequelae (1, 2). Management is threatened by 
antimicrobial resistance (AMR) to the first line treatment azithromycin (3), and treatment options 
are limited (4). Trachoma is the leading infectious cause of blindness worldwide (5), caused by ocular 
Chlamydia trachomatis (CT) infection. A key component of the WHO trachoma elimination strategy 
is mass drug administration (MDA) with 20mg/kg azithromycin, up to a maximum of 1g in adults. 
MDA is recommended annually for a minimum of three years in districts where trachoma is endemic 
(trachomatous inflammation-follicular (TF) prevalence ≥10% in 1-9-year-olds) (6). Temporary 
increases in carriage of macrolide resistant Streptococcus pneumoniae, Staphylococcus aureus and 
Escherichia coli have been observed following MDA (7). Thus, whilst MDA with azithromycin may 
have significant benefits through reducing prevalence of active trachoma, ocular CT infection (8), 
genital CT infection (9) and even child mortality (10), these may be undermined by subsequent 
emergence of AMR in target and non-target organisms. 
Azithromycin resistance rates vary worldwide, with reports of 79.4% in Australia (11, 12) and over 
70% in Japan (13). Limited data exist on resistance prevalence in Pacific Basin nations. Approximately 
10% of infected patients treated with 1g azithromycin develop macrolide resistance post-treatment 
(14, 15), with resistance mediated by single nucleotide polymorphisms (SNPs) most frequently 
observed at adenosine nucleotides at positions 2058 and 2059 within the 23S rRNA gene (16). 
Resistance selecting pressures, such as mass treatment programs, may worsen this situation. This 
raises the question of whether secondary beneficial impacts of azithromycin MDA (reduced 
morbidity and mortality) should be weighed against potential negative impacts (AMR). Given the 
large populations treated with azithromycin by trachoma elimination programmes  (over 800 million 
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doses provided to programmes by the International Trachoma Initiative as of December 2018 (17)), 
we aimed to ascertain the effect of a  trachoma programme MDA distribution on M. genitalium 
prevalence and azithromycin resistance. 
Methods 
Study Population
Patient samples and data were collected as described previously (9). Briefly, women aged 16–49 
years attending three community antenatal clinics (ANCs) in Honiara, Solomon Islands, were 
recruited over 10 days in August 2014. Participants were invited to take part pre-MDA. A new group 
of women aged 16-49 years was enrolled in the same clinics 10 months post-MDA, over 5 days in 
July 2015. Demographic and clinical data were collected by clinic nursing staff. At both time-points, 
two self-taken vulvo-vaginal swabs were collected and stored at -20°C in the recruiting clinic; one 
was tested for CT and Neisseria gonorrhoeae using the ProbeTec CT/GC assay (Becton Dickinson, 
USA) at the Solomon Islands national reference laboratory, whilst the other was shipped on dry ice 
to the London School of Hygiene & Tropical Medicine (LSHTM, UK) and stored at -20°C. Swabs 
matched to CT-negative samples from reference testing were included in this study (CT positive 
samples were allocated for other research (9)), and were transported dry on dry ice to St George’s, 
University of London, UK.  
Pathogen detection
DNA from swabs was eluted in 1ml Phosphate Buffered Saline (PBS) (Sigma-Aldrich, USA) followed 
by vortexing for 15s and brief centrifugation. The entire eluate was removed in preparation for 
testing. During preparation, one media control sample of PBS was included for every 32 samples. 
DNA extraction was carried out by the QIASymphony SP/AS instrument (Qiagen, Germany) with the 
Virus/Pathogen Mini kit using the Complex 200 protocol, with a 60µl elution volume. M. genitalium 
was tested for using FTD Urethritis Plus (FTDUP) PCR kit (Fast-Track Diagnostics, Luxembourg) on the 
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Rotor-Gene Q (Qiagen) according to manufacturer’s instructions. FTDUP positivity was defined as an 
exponential amplification signal crossing a threshold of 0.05 normalised fluorescence, as per 
standard practice at South West London Pathology, St George’s University Hospitals NHS Foundation 
Trust. For a valid, (1) the internal control had to be positive and have a cycle threshold (Cq) value 
≤33, or if above 33, within ±3.3 Cq of the extraction control’s Cq; and (2) positive, media and no-
template controls had to pass. The person carrying out the testing was blind to all patient data, 
including reference CT/NG test results.
M. genitalium 23S rRNA genotyping
Samples identified as M. genitalium positive by FTDUP underwent Sanger sequencing of the domain 
V region of the 23S rRNA gene to identify SNPs at positions 2058 and 2059 (E. coli numbering) 
associated with high level macrolide resistance. 2µl extracted DNA was amplified using previously 
validated primers (16) using the Multiplex PCR kit (Qiagen) according to manufacturer’s instructions 
on a GS-1 thermal cycler (G-Storm, UK). Pre-MDA samples were amplified as follows: 95°C 15 
minutes, 45 cycles of 94°C 30s, 56.5°C 90s and 72°C 90s, with a final step of 72°C 10 minutes. Post-
MDA samples were amplified as follows: 94°C 15 minutes, 45 cycles of 94°C 30s, 60°C 3 minutes and 
72°C 90s with a final step of 72°C 10 minutes. If the initial 2µl of extracted DNA used as template 
failed to generate product, then PCR was repeated with 5µl eluate.
PCR products from pre-MDA samples were analysed by Bioanalyzer DNA 1000 kit (Agilent, USA) and  
extracted DNA samples submitted to Source Bioscience (Cambridge, UK) for clean-up and 
sequencing. Post-MDA PCR products were analysed using 2% size select gel on the E-gel system 
(Thermo Fisher, USA). Desired bands were extracted and underwent clean-up with MinElute 
Reaction Clean-up Kit (Qiagen). DNA concentrations were assessed using HS DNA kit on the Qubit 3.0 
(Thermo Fisher) and adjusted to meet the Source Bioscience requirements. Sequencing analysis 
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involved alignment to M. genitalium G37 strain to check for resistance-associated SNPs, using Clustal 
Omega software (18, 19).  
Strain typing
As there was insufficient DNA for whole genome sequencing (WGS) , we performed a validated dual 
locus sequence typing (DLST)(20). Approximately 600µl of residual swab eluate from M. genitalium 
positive samples underwent DNA extraction using FastDNA® SPIN Kit and the FastPrep® 5G 
Instrument (MP Biomedicals, USA) according to manufacturer’s instructions, with the following 
modification: 600µl eluate buffer was added to  600µl 1% SDS, 60mM EDTA and 100mM Tris buffer 
(pH8). DLST was performed using MG191 (mgpB) SNP typing combined with analysis of the MG309 
variable number tandem repeat, as described previously (3, 20, 21). PCR was performed using 
Multiplex PCR kit according to manufacturer’s instructions. 5µl extracted DNA was used in each PCR 
reaction. If no amplicons were produced, DNA volume was increased to 15µl. PCR was carried out on 
a T-100 thermocycler (Bio-Rad, USA): 95°C 15 minutes, 45 cycles of 94°C 30s, 58°C 90s, and 72°C 90s, 
and a final extension of 72°C 10 minutes. PCR products underwent processing as described above for 
M. genitalium 23S rRNA genotyping of post-MDA samples. Where sequences were available for both 
loci for a sample, sequences were concatenated and underwent alignment by Clustal Omega (18, 
19). Phylogenetic trees were produced using RaxML (22) and figures with Figtree v1.4.3 (23).
Sample size and statistical analysis
Sample size was constrained by the genital CT study design (9), which aimed to recruit a total of 375 
women on the assumption of a change in prevalence from 20% to less than 10%. We assumed 
similar rates of infection and impact for M. genitalium. We did not anticipate identifying any 
azithromycin resistance pre-MDA due to azithromycin only being recommended for MDA for 
trachoma elimination in the Solomon Islands. Based on an estimated M. genitalium prevalence of 
10% post-MDA and 12% azithromycin resistance development (15) between pre- and post-MDA, we 
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expected to identify an additional two cases of azithromycin resistance post-MDA compared to pre-
MDA. Logistic regression was used to calculate the Odds Ratios (OR) for factors associated with M. 
genitalium infection. Variables tested included patient demographics, symptoms, patient-reported 
previous treatment of other STIs, and patient-reported receipt of MDA. Patients were not required 
to have a full dataset to be included in the analysis and data were only excluded where they were 
missing for calculation of ORs (table 1).  Analysis was carried out using Stata V10.1 (STATACorp, 
USA). All sequences in this study have been submitted to EMBL-ENA (accession: PRJEB26624).
Results
Population Characteristics 
Figure 1 represents the pre- and post-MDA sample flow. Table 1 displays study population 
characteristics. Among pre-MDA and post-MDA patients included in the analysis, 38/236 (16.1%) 
versus 22/256 (8.6%; p=0.011) respectively reported having a symptom indicative of an STI 
(dyspareunia, abnormal vaginal discharge or genital ulcer) within the previous month. 126 (49.2%) 
post-MDA patients reported receiving azithromycin as part of MDA; for four patients data were 
unavailable.
Impact of MDA on M. genitalium prevalence and azithromycin resistance 
No difference was found between pre- and post-MDA M. genitalium prevalence; 11.9% [95% 
Confidence Interval (CI) 8.3-16.6%; n=28/236] versus 10.9% [95% CI: 7.9-15.4%; n=28/256] 
respectively.  Azithromycin resistance genotypes were generated for 21/28 women pre-MDA and 
22/28 women post-MDA (Figure 1), no azithromycin resistance conferring SNPs at the 2058 or 2059 
positions of 23S rRNA were found at either time point. No azithromycin resistance-conferring SNPs 
at 2058 or 2059 positions of 23S rRNA were found at either time point. 
Risk factors for M. genitalium infection
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No risk factors were significantly associated with M. genitalium infection pre-MDA. 17.6% (22/125) 
of women who reported not receiving MDA were found to be M. genitalium positive compared to 
4% (5/126) of women who reported receiving MDA (odds ratio of being M. genitalium positive after 
MDA receipt: 0.19 (p=0.001)). Despite post-MDA women having fewer STI symptoms than pre-MDA 
women, and being more likely to have been treated for an STI in the previous 12 months, these 
factors were not associated with reduced likelihood of being M. genitalium positive post-MDA. 
Strain typing
Sequencing was successful for both MG191 and MG309 loci for 25/28 pre-MDA and 16/28 post-MDA 
samples. Sequence types diverged into two main lineages: MG1 [n=34] and MG2 [n=7] (bootstrap 
value 100%; Figure 2). The proportion of MG2 lineage samples changed from 1/25 (4%) pre-MDA to 
6/16 (37.5%) post-MDA respectively (p<0.01; Fisher’s exact test), suggesting a degree of strain 
replacement between the time-points. Overall, only 5/27 (18.5%) of post-MDA M. genitalium 
positive patients received azithromycin, including only 2/10 MG1 and 0/5 MG2 DLSTs of those 
sequenced. Azithromycin treatment status was not available for one woman with MG2 strain type 
post-MDA. No other bootstrap values between individual M. genitalium infections were sufficiently 
high to confidently separate strains to any higher resolution. 
Discussion 
In this secondary analysis of ANC attendees in the Solomon Islands, we found no change in 
prevalence of M. genitalium infection nor appearance of 23S rRNA genotypic markers of 
azithromycin resistance in the interval from before to 10 months after a single round of azithromycin 
mass drug administration for trachoma elimination. We also demonstrated azithromycin 
receiptduring MDA was associated with reduced likelihood of post-MDA M. genitalium positivity. A 
change in composition of M. genitalium strain types in those sampled was observed between pre- 
and post-MDA patients.
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Factors that may affect impact of MDA on STI transmission include antibiotic efficacy and treatment 
failure, MDA coverage especially in high STI-risk and STI-burdened populations, and infection 
persistence. Contributions of these factors to reducing STI prevalence through direct treatment, or 
longer-term by decreasing onward transmission, need to be considered in relation to the time-
period of MDA impact assessment.
Importantly, azithromycin receipt as part of the MDA was reported in only 49.2% of women post-
MDA. Programme MDA coverage estimates are often unreliable as coverage is mostly calculated by 
doses given divided by estimated resident population, determined at the most recent census (24); 
the denominator may be out-of-date or otherwise unrepresentative of the population present at the 
time of MDA. Furthermore, MDA coverage data are generally not available by age and sex. It was 
therefore not possible to compare MDA receipt between the study and wider populations. Neither 
data regarding sexual history between MDA receipt and study recruitment nor MDA receipt amongst 
sexual partners were collected. These data could have provided insight into potential re-infection 
risk and an explanation for why M. genitalium prevalence was unchanged between pre- and post-
MDA populations. The study was performed as two independent cross-sectional surveys within 
three ANCs, patients of which are perhaps at a different STI risk levels than the general population. 
Importantly, sample size was determined by the genital CT study design, and therefore may not have 
been sufficient for detecting smaller overall prevalence changes or azithromycin resistance 
emergence. If the five M. genitalium positive women who had reported MDA receipt post-MDA 
were positive because of persistence of infection following failure of azithromycin to cure infection, 
one might expect some of these to have developed azithromycin resistance. As no resistance 
associated mutations were detected this would suggest that these patients were most likely infected 
post-MDA, consistent with high rates of transmission in the population and may also explain the 
high prevalence of infection. It was not possible to sequence a proportion of the M. genitalium 
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positive samples (7/28 (25%) pre-MDA; 6/28 (21.4%) post-MDA) for 23S mutations, and it is possible 
that these samples contained macrolide resistant strains. It cannot be discounted that those we 
were unable to sequence were not true positives.  Unfortunately, there is are no published 
sensitivity and specificity data on FTDUP performance for detection of M. genitalium sensitivity and 
specificity. In another body of work we found a sensitivity and specificity of to be 100% and 
specificity to be 95.8%, respectively, albeit in a limited sample size of 122 (unpublished data). 
Therefore, we do not consider test performance to potentially be a major limiting factor in correctly 
identifying MG positive and negative samples. Finally, it was not possible to test CT positives for M. 
genitalium, due to their allocation to another study, which may have led to an underestimate of M. 
genitalium positivity both pre- and post-MDA given that co-infection with CT and M. genitalium is 
common (25-27). Additionally, as a significant reduction in CT prevalence was found in the primary 
analysis, exclusion of CT positives (n=103, pre-MDA n=60, post-MDA n=43) may be a source of bias 
as a greater proportion of CT positives was excluded from the pre-MDA samples versus the post-
MDA samples. 
Despite these limitations, our risk factor analysis provides strong evidence that those receiving 
azithromycin MDA had reduced odds of being M. genitalium positive, implying that increasing MDA 
coverage may be key in achieving greater M. genitalium prevalence impact , at least in the short-
term. Significant scope for increasing MDA uptake in this population exists as only 49.2% of women 
recruited post-MDA reported azithromycin receipt. Post-MDA enrolment occurred approximately 
ten months after baseline, making it unlikely that women enrolled at this time point would have 
been pregnant during MDA, an explanation that might otherwise account for low azithromycin 
uptake. However, we cannot discount the possibility that some women avoided MDA through fear 
of taking treatment while trying to conceive. It is unclear whether 10-months post-MDA is the most 
appropriate time-point to measure MDA impact on prevalence, as any initial M. genitalium 
prevalence reduction may have waned by 10 months. In remote island populations, this might be 
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expected to occur if there were relatively high rates of sexual transmission of endogenous, rather 
than imported, M. genitalium infection. More data on transmission dynamics and STI epidemiology 
within the Solomon Islands would help to establish the most appropriate time-points for measuring 
MDA impact on STI prevalence.
These data may also help identify factors associated with M. genitalium infection. Our risk factor 
analysis did not identify any factors other than self-reported MDA receipt, despite high prevalences 
pre- (11.9% and post- (10.9%) MDA. This may be due to the relatively small sample size, or the 
variables collected not including factors that are important M. genitalium infection correlates in this 
population. Risk factor analyses are useful in helping target prevention and control strategies and 
interventions, but there are limited data on M. genitalium prevalence in pregnant women. The high 
prevalence of C. trachomatis and N. gonorrhoeae previously reported (9) and M. genitalium in our 
study, both pre- and post-MDA, indicates that this population would benefit from effective STI 
prevention strategies. Further epidemiological investigations in different population groups is 
warranted to help develop, monitor and evaluate these strategies, including assessing associations 
between M. genitalium infection and adverse pregnancy outcomes.
It is possible that single dose azithromycin, used during MDA, was not as effective against M. 
genitalium as against CT, explaining the lack of overall impact on M. genitalium prevalence. M. 
genitalium cure rates with 1g azithromycin are known to be as low as 81%, independent of pre-
existing macrolide resistance (14), much lower than CT cure rates (28). However, as strong evidence 
existed of reduced likelihood of being M. genitalium positive in those who reported MDA receipt, we 
do not believe this to be a major explanation for our results. 
We were unable to perform WGS for strain typing because of insufficient DNA. However, WGS for 
M. genitalium has not yet been validated for phylogenetic analysis, with concerns raised about 
degrees of genome recombination (29). Using DLST, we identified two major strain lineages, as well 
as detected an increase in MG2 proportion post-MDA. This shift might have occurred due to 
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differences in characteristics of infection such as bacterial load, leading to variable antibiotic 
susceptibility (30), which may introduce sequencing bias. No post-MDA patients with MG2 and only 
2/10 with MG1 reported receiving azithromycin, suggesting low likelihood of strain replacement 
occurring directly because of azithromycin receipt. However, it is possible that MDA effects on strain 
representation in the general population may have been transmitted to the ANC population. 
Whether this is measurable 10 months after MDA is questionable and other factors, such as natural 
bacterial evolution, changes in sexual networks over time, or stochastic changes in a relatively small 
effective population size, may account for these findings.
Absence of azithromycin resistance in M. genitalium in the Solomon Islands contrasts with high 
resistance prevalence in other parts of the Western Pacific Region, namely Australia and Japan (31, 
32). The Solomon Islands has low azithromycin usage, with MDA for trachoma elimination being the 
only recommended use within the country at the time of MDA. In contrast, in other, especially high 
income, countries, azithromycin is indicated for a number of conditions, including respiratory 
infections (33). M. genitalium has only one 23S rRNA locus making it particularly susceptible to 
selection of resistant strains, which occurs in approximately 10% of treated patients (14, 15). Cure 
rates are observed to decline where 1g is part of the national standard for STI treatment (15, 30). 
We may therefore have expected to observe an increased prevalence of azithromycin resistance 
markers being selected given MDA coverage. However, relatively low coverage in the ANC 
population combined with relatively low sample size may explain why we did not detect emergent 
AMR. It is possible that repeat MDA rounds may select for resistance through increased selection 
pressure, undermining the possible benefits of actual receipt of azithromycin during MDA that we 
observed in this round. More studies focussing on general populations and over multiple MDA 
rounds would more fully evaluate the risk of STI AMR development following MDA. 
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In this first study, assessing the impact of a single round of azithromycin MDA for trachoma 
elimination on M. genitalium prevalence and AMR among ANC attendees in an island population, we 
did not detect reduction in M. genitalium prevalence nor the appearance of azithromycin resistance 
following a single round of MDA with 1g azithromycin for trachoma elimination. However, receipt of 
azithromycin was associated with reduced odds of being M. genitalium positive post-MDA. A 
number of factors may account for these findings including low MDA coverage, high re-infection risk 
from untreated partners, insufficient sample size, time gap between pre and post-MDA sample 
collection, and perhaps a lack of 1g azithromycin efficacy for treatment of M. genitalium. These 
findings cannot otherwise be confidently explained by an observed change in strain representation 
between pre- and post-MDA sample sets. Benefits of MDA for trachoma elimination, and in national 
programmes for other neglected tropical diseases, must continue to be weighed against potential 
negative consequences, such as AMR emergence. Further investigation of the impact of multiple 
rounds of azithromycin MDA on M. genitalium prevalence and AMR in different populations and 
settings is warranted. 
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1
Logistic regression risk factor analysis for being MG positive pre-MDA and post-MDA
Pre-MDA Post-MDA
Univariate analysis Univariate Analysis
Characteristic No. of        
participants
No. (%) 
with MGa
OR 95%CI P-value No of        
participants
No. (%) 
with MG
OR 95%CI P-value
Age group (years)
15-24 68 9 (13.2) 1.00 113 13 (11.5) 1.00
25-34 104 10 (9.6) 0.70 0.27-1.82 0.461 114 11 (9.7) 0.82 0.35-1.92 0.650
35-44 39 6 (15.4) 1.19 0.39-3.64 0.758 28 4 (14.3) 1.28 0.38-4.28 0.686
45-64b 11 0 (0) - - - 0 0 (0) - - -
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Data 
unavailable
14 1
Clinic
K 94 11 (11.7) 1.00 77 10 (13.0) 1.00
M 64 7 (10.9) 0.93 0.34-2.53 0.882 86 12 (14.0) 1.09 0.44-2.68 0.857
R 75 9 (12.0) 1.03 0.40-2.63 0.953 92 6 (6.5) 0.47 0.16-1.35 0.160
Data 
unavailable
2 1
Ethnicity
Melanesian 212 25 (11.8) 1.00 228 26 (11.4) 1.00
Other 14 2 (14.3) 1.25 0.26-5.90 0.781 24 2 (8.3) 0.71 0.16-3.18 0.650
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Data 
unavailable
10 4
Urban/Rural
Urban 214 22 (10.3) 1.00 197 23 (11.7) 1.00
Rural 6 1 (16.7) 1.75 0.19-15-63 0.618 46 3 (6.5) 0.53 0.15-1.84 0.316
Data 
unavailable
16 13
Education
233 25 (10.7) 1.09 0.99-1.19 0.082 255 28 (11.0) 0.94 0.86-1.03 0.196
Data 
unavailable
6 1
Currently married
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No 37 7 (18.9) 1.00 51 6 (11.8) 1.00
Yes 192 19 (9.9) 0.47 0.18-1.22 0.120 198 21 (10.6) 0.89 0.34-2.33 0.813
Data 
unavailable
7 7
Living with partner
No 40 8 (20.0) 1.00 29 4 (13.8) 1.00
Yes 184 17 (9.2) 0.41 0.16-1.02 0.056 217 23 (10.6) 0.74 0.24-2.32 0.606
Data 
unavailable
12 10
STI in last 12 
months
No 224 25 (11.2) 1.00 229 23 (10.0) 1.00
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Yes 8 2 (25.0) 2.65 0.51-13.9 0.247 22 4 (18.2) 1.99 0.62-6.39 0.247
Data 
unavailable
4 5
Symptoms
No 188 23 (12.2) 1.00 222 26 (11.7) 1.00
Yes 37 3 (8.1) 0.63 0.18-2.23 0.476 22 1 (4.5) 0.36 0.05-2.78 0.327
Data 
unavailable
11 12
Gonorrhoea 
positivec
No 228 25 (11.0) 1.00 240 28 (11.7) 1.00
Yes 5 2 (40.0) 5.41 0.86-33.98 0.072 15 0 (0) - - -
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Data 
unavailable
3 1
TV Positive
Negative 146 14 (9.6) 1.00 135 16 (11.9) 1.00
Positive 87 13 (14.9) 1.66 0.74-3.71 0.220 120 12 (10.0) 0.83 0.37-1.83 0.637
Data 
unavailable
3 1
Received MDA
No N/A N/A N/A N/A N/A 125 22 (17.6) 1.00
Yes N/A N/A N/A N/A N/A 126 5 (4.0) 0.19 0.07-0.53 0.001
Data 
unavailable
5
2 Table 1 Risk factors for M. genitalium infection, including demographic data
3 Risk factor analysis for Mycoplasma genitalium (MG) prevalence; a MG positive defined by FTD Urethritis Plus Kit; b Age group 45-64 years predicted failure perfectly
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4 c Positive by BD ProbeTec and/or FTD Urethritis Plus Kit. 
5
6
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Figure 1. Sample flow. MDA: Mass drug administration; FTD: Fast Track Diagnostics; MG: Mycoplasma 
genitalium; BD: Becton Dickinson; CT: Chlamydia trachomatis. 
84x67mm (300 x 300 DPI) 
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Figure 2. Phylogenetic tree of M. genitalium positive samples using Dual Locus Sequence Typing. Red 
denotes samples collected pre-MDA and blue denotes samples collected post-MDA; Bootstrap value between 
MG1 and MG2 =100%. Scale: mean number of nucleotide substitutions per site 
43x29mm (300 x 300 DPI) 
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